ライフサイエンスコーパス: autoimmune disease

1 vaccines and immunotherapies for cancer and autoimmune disease.

2 a mouse model with genetic susceptibility to autoimmune disease.

3 vaccine (ZVIN) were evaluated in adults with autoimmune disease.

4 ely associated with the development of human autoimmune disease.

5 is essential to prevent immunopathology and autoimmune disease.

6 he roles of lncRNAs in the immune system and autoimmune disease.

7 in multiple models of infection, cancer and autoimmune disease.

8 unter pathology in models of inflammation or autoimmune disease.

9 d the clinical outcome of neuro-inflammatory autoimmune disease.

10 e, sex, race, smoking status, and history of autoimmune disease.

11 xtualizing the epitope spreading observed in autoimmune disease.

12 e new insight into mechanisms of controlling autoimmune disease.

13 specificity may contribute susceptibility to autoimmune disease.

14 ty for the discovery of novel biomarkers for autoimmune disease.

15 us to posit a cumulative hit hypothesis for autoimmune disease.

16 (NK) cell function and promotes a lupus-like autoimmune disease.

17 of Erdr1 a potential therapeutic target for autoimmune disease.

18 represent an effective means for modulating autoimmune disease.

19 ptides that act as self-epitopes in clinical autoimmune disease.

20 dent NKp46(+) ILCs in the development of CNS autoimmune disease.

21 ry of host proteins by pathogens can lead to autoimmune disease.

22 ssive combined immune deficiency with severe autoimmune disease.

23 ll subset whose expansion is correlated with autoimmune disease.

24 f-recognition, conferring heightened risk of autoimmune disease.

25 w therapeutic horizons in patients with this autoimmune disease.

26 ling for age, sex, race, smoking status, and autoimmune disease.

27 hes for limiting the effects of IgG-mediated autoimmune disease.

28 lity to migrate into inflamed tissues during autoimmune disease.

29 tential as a therapeutic target for treating autoimmune diseases.

30 s play an important role in the pathology of autoimmune diseases.

31 to cure human chronic infections, cancer, or autoimmune diseases.

32 en results in hematopoietic malignancies and autoimmune diseases.

33 e effect of treatment on TH17 cells in human autoimmune diseases.

34 em cell transplantation (AHSCT) may resemble autoimmune diseases.

35 mbers/functions has been shown to ameliorate autoimmune diseases.

36 tiple, shared allelic associations with many autoimmune diseases.

37 tiate into pathogenic Th17 cells can trigger autoimmune diseases.

38 y widespread diseases, such as allergies and autoimmune diseases.

39 uggest a contribution to the pathogenesis of autoimmune diseases.

40 es to pathogens or tissue damage, and drives autoimmune diseases.

41 a class of small noncoding RNAs, in diverse autoimmune diseases.

42 nflammatory cytokine implicated a variety of autoimmune diseases.

43 ic use in early life and the risk of certain autoimmune diseases.

44 ches for the treatment of TH17-cell-mediated autoimmune diseases.

45 Abs as well as the frequency and severity of autoimmune diseases.

46 tions or effects in models of infectious and autoimmune diseases.

47 ammation in different experimental models of autoimmune diseases.

48 ions of this selectivity filter give rise to autoimmune diseases.

49 e as a key dysregulated gene in RA and other autoimmune diseases.

50 NAs, and whose malfunctioning causes serious autoimmune diseases.

51 hR agonists for multiple sclerosis and other autoimmune diseases.

52 r implicated in the pathogenesis of multiple autoimmune diseases.

53 (ASIT) would allow for improved treatment of autoimmune diseases.

54 these molecules and pathways in cancers and autoimmune diseases.

55 e long been considered potential triggers of autoimmune diseases.

56 ectronic neuromodulation in inflammatory and autoimmune diseases.

57 romising target for treatment of a number of autoimmune diseases.

58 herapeutic possibilities in inflammatory and autoimmune diseases.

59 to the initiation and progression of various autoimmune diseases.

60 particular, cancer, metabolic syndromes, and autoimmune diseases.

61 be considered for therapeutic approaches of autoimmune diseases.

62 insight for understanding the regulation of autoimmune diseases.

63 potential for the treatment of allergic and autoimmune diseases.

64 the cytokine's activity in inflammatory and autoimmune diseases.

65 the therapy of inflammation and, likely, of autoimmune diseases.

66 c role of reduced NOX2-derived ROS levels in autoimmune diseases.

67 ft rejection, graft versus host disease, and autoimmune diseases.

68 vaccines and immunotherapies for infectious autoimmune diseases.

69 ts with cancer, solid organ transplants, and autoimmune diseases.

70 ent of novel therapies for the prevention of autoimmune diseases.

71 and other antibody-mediated inflammatory and autoimmune diseases.

72 rovide new therapies for transplantation and autoimmune diseases.

73 D alleles dominantly protect from particular autoimmune diseases.

74 st antigens has been associated with several autoimmune diseases.

75 FIH1(T946)) that is associated with multiple autoimmune diseases.

76 , thus preventing the development of certain autoimmune diseases.

77 ymorphisms (SNPs) previously associated with autoimmune diseases.

78 r 17 (Th17) cells plays an essential role in autoimmune diseases.

79 ess hold high potential for the treatment of autoimmune diseases.

80 n multiple sclerosis and other Th17-mediated autoimmune diseases.

81 ith other pathological conditions, including autoimmune diseases.

82 or implicated in the pathogenesis of various autoimmune diseases.

83 s in microbial infections, malignancies, and autoimmune diseases.

84 nic inflammation can lead to inflammatory or autoimmune diseases.

85 l loci and their pathways involved in PD and autoimmune diseases.

86 n important regulator of immune responses in autoimmune diseases.

87 ections can contribute to the development of autoimmune diseases.

88 ion and established its protective effect in autoimmune diseases.

89 lay an important role in the pathogenesis of autoimmune diseases.

90 novel therapies for transplant rejection and autoimmune diseases.

91 ficiency causes lethal, CD4(+) T cell-driven autoimmune diseases.

92 of utilizing naive T cells for understanding autoimmune diseases.

93 fective in patients with antibody-associated autoimmune diseases.

94 uishing normal from tumor tissue and trigger autoimmune diseases.

95 channel is observed at the onset of several autoimmune diseases.

96 ls may be a potential target for therapy for autoimmune diseases.

97 the same direction of effect for allergy and autoimmune diseases.

98 not be sufficient to prevent tissue-specific autoimmune diseases.

99 an constant eQTLs in GWAS signals of several autoimmune diseases.

100 ing therapeutic agents against TH17-mediated autoimmune diseases.

101 une response, and is also the main driver of autoimmune diseases.

102 dates for the prevention and amelioration of autoimmune diseases.

103 ome a focus of research in the area of human autoimmune diseases.

104 ole of these cells in human inflammatory and autoimmune diseases.

105 nt seemed to be a general characteristic for autoimmune diseases.

106 t self, and thus to avoid the development of autoimmune diseases.

107 immune response, as shown for infectious and autoimmune diseases.

108 urette's/chronic tic disorders (TD/CTD) with autoimmune diseases (ADs) is uncertain.

109 Autoimmune diseases affect 7.5% of the US population, an

110 ravis (MG) is a prototypical B cell-mediated autoimmune disease affecting 20-50 people per 100,000.

111 asculitis (AAV) constitutes life-threatening autoimmune diseases affecting every organ, including the

112 that recapitulate causative mutations in the autoimmune disease Aicardi-Goutieres syndrome demonstrat

113 ife-threatening consequence of treatment for autoimmune disease (AID) and an emerging clinical phenom

114 argeted tolerance induction and treatment of autoimmune diseases, allergic disorders, and graft rejec

115 rograms operating during acute inflammation, autoimmune diseases, allergic inflammation, pregnancy, c

116 isturbances in the immune repertoire such as autoimmune diseases, allergy, and leukemia, but it can a

117 zed GWAS data from a selection of archetypal autoimmune diseases among 138511 individuals of European

118 y for viral RNA, with major implications for autoimmune disease and cancer.

119 better understanding the molecular basis for autoimmune disease and cancer.

120 lymphocytes that protect against infection, autoimmune disease and cancer.

121 ar helper (TFH) cell pool is associated with autoimmune disease and Def6 has been identified as an SL

122 Ankylosing spondylitis is an inflammatory autoimmune disease and evidence showed that ankylosing s

123 e findings suggest a role for eosinophils in autoimmune disease and have important implications for t

124 iated with positive and negative outcomes in autoimmune disease and infection.

125 signature associated with susceptibility to autoimmune disease and linked this to extensive sex-depe

126 s of DNA variants affecting both the risk of autoimmune disease and quantitative immune variables pro

127 Patients with a history of autoimmune disease and those who had received previous t

128 ppressive therapy, such as that required for autoimmune disease and transplantation.

129 linical examination findings, and history of autoimmune disease and/or malignancy, as well as topical

130 Th17 cells are major players in multiple autoimmune diseases and are developmentally contingent o

131 riants at these loci also affect the risk of autoimmune diseases and blood malignancies and influence

132 The central role of myeloid cells in driving autoimmune diseases and cancer has raised interest in ma

133 egulatory T cells (Tregs) is dysregulated in autoimmune diseases and cancer.

134 be critical in preventing the development of autoimmune diseases and cancer.

135 ulatory drugs are increasingly used to treat autoimmune diseases and cancer.

136 ovel therapeutic target for inflammatory and autoimmune diseases and diabetes, exerts anti-inflammato

137 he treatment of metabolic disorders, cancer, autoimmune diseases and etc.

138 d attenuates the progression and severity of autoimmune diseases and experimental colitis.

139 ovide novel mechanistic insights into PD and autoimmune diseases and identify a common genetic pathwa

140 t is a target of therapeutic intervention in autoimmune diseases and lymphoma.

141 Growing insight into the pathogenesis of autoimmune diseases and numerous studies in preclinical

142 highly promising target for the treatment of autoimmune diseases and other conditions.

143 factors contributing to the pathogenesis of autoimmune diseases and the mechanisms involved is still

144 Finally, the role of the laminins in autoimmune diseases and transplantation will be discusse

145 , 10 (5%) with an infection, 15 (8%) with an autoimmune disease, and 76 (39%) with other diseases.

146 ignaling is associated with immunopathology, autoimmune disease, and cancer progression.

147 implications for suppressing inflammation in autoimmune diseases, and for preventing neuronal damage

148 bone marrow and solid organ transplantation, autoimmune diseases, and tissue and organ repair.

149 cytes in various diseases including cancers, autoimmune diseases, and virus infections.

150 hatase Ptpn22, a major predisposing gene for autoimmune disease, are resistant to the suppressive eff

151 c anti-Ro/SSA testing even in the absence of autoimmune diseases as immunomodulating therapies may be

152 logy in multiple sclerosis and perhaps other autoimmune diseases as well.

153 Autoimmune disease-associated variants are preferentiall

154 ne system responses and in the prevalence of autoimmune diseases between males and females, there is

155 l-specific ablation of murine Gclc prevented autoimmune disease but blocked antiviral defense.

156 s that was also represented in patients with autoimmune diseases but not those with other diseases.

157 the BACH2 locus are associated with several autoimmune diseases, but BACH2 mutations that cause Mend

158 IL-23/IL-17 pathway is important in multiple autoimmune diseases, but its effect on lupus pathology r

159 kine CXCL10 has been associated with several autoimmune diseases, but its participation in BP pathoph

160 r its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antago

161 CD40-CD40L pathway is implicated in various autoimmune diseases, but the activity status of this pat

162 latory T (tTreg) cells are key to preventing autoimmune diseases, but the mechanisms involved in thei

163 y participate in the pathogenesis of several autoimmune diseases, but the nature of miRNAs contributi

164 ently been implicated in the pathogenesis of autoimmune diseases by various mechanisms, including for

165 Mutations in AIRE cause a monogenic autoimmune disease called autoimmune polyendocrinopathy-

166 riety of immune-related pathologies, such as autoimmune diseases, cancers, and chronic infections tha

167 options for a number of diseases, including autoimmune diseases, cardiovascular disease and cancer.

168 todermal dystrophy (APECED), a T cell-driven autoimmune disease caused by impaired central tolerance,

169 Psoriasis is an autoimmune disease characterized by abnormal differentia

170 ic lupus erythematosus (SLE) is an incurable autoimmune disease characterized by autoantibody deposit

171 c lupus erythematosus (SLE) is a multi-organ autoimmune disease characterized by autoantibody product

172 en's syndrome (SS) is a chronic inflammatory autoimmune disease characterized by diminished secretory

173 Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and

174 Systemic sclerosis is an autoimmune disease characterized by fibrosis of skin and

175 allmark of Sjogren's syndrome (SS), a common autoimmune disease characterized by lymphocytic infiltra

176 Sjogren's syndrome (SS) is a common chronic autoimmune disease characterized by lymphocytic infiltra

177 Systemic sclerosis is an autoimmune disease characterized by T-cell infiltration

178 Antiphospholipid syndrome (APS) is an autoimmune disease characterized by venous thromboemboli

179 ental pollutants have been shown to modulate autoimmune disease development.

180 us DNA and play a role in tumor immunity and autoimmune disease development.

181 Multiple Sclerosis (MS) is an autoimmune disease driving inflammatory and degenerative

182 Autoimmune diseases feature T cells that are resistant t

183 Current therapies for autoimmune diseases focus on treating the symptoms rathe

184 rk may also apply to a number of more common autoimmune diseases for which the underlying genetics an

185 c autoimmunity, but a role in organ-specific autoimmune disease has not been demonstrated.

186 A higher frequency of autoimmune diseases has been observed in GSD-1b patients

187 ls of IL-15 expression with inflammatory and autoimmune diseases has led to the development of variou

188 Genomewide association studies of autoimmune diseases have mapped hundreds of susceptibili

189 s and establishment of clinical tolerance in autoimmune diseases have proven to be challenging.

190 on has been associated with inflammatory and autoimmune diseases; however, the factors contributing t

191 y properties of B cells have been studied in autoimmune diseases; however, their role in allergic dis

192 risk variants conveying risk of both PD and autoimmune diseases (ie, pleiotropy) and to identify new

193 2 subunits might be exploited to treat other autoimmune diseases.IL-12p35 is common to IL-35 and IL-1

194 cells and the establishment of a lupus-like autoimmune disease in mice.

195 ulatory T cells (Tregs) and a fatal systemic autoimmune disease in scurfy mice.

196 ave been shown to be associated with several autoimmune diseases in addition to T1D.

197 cription factor Prdm1 has been implicated in autoimmune diseases in humans through genome-wide associ

198 in, is one of the most common organ-specific autoimmune diseases in humans.

199 improvement of clinical symptoms of certain autoimmune diseases including autoimmune hepatitis (AIH)

200 Disease activity of many autoimmune diseases including multiple sclerosis (MS) is

201 Autoimmune diseases, including Aicardi-Goutieres syndrom

202 ve been previously demonstrated in different autoimmune diseases, including human type 1 diabetes, bu

203 e less than 0.05 with overlap between PD and autoimmune diseases, including known PD loci adjacent to

204 genes had a strong association with multiple autoimmune diseases, including lupus, scleroderma and Sj

205 known factors involved in the development of autoimmune diseases, including MS.

206 ted in the etiology and treatment of several autoimmune diseases, including multiple sclerosis (MS).

207 drome (MetS) is thought to influence several autoimmune diseases, including multiple sclerosis (MS).

208 Th17 cells play a critical role in autoimmune diseases, including multiple sclerosis and it

209 s, OR = 2.02 in African Americans) and other autoimmune diseases, including primary Sjogren's syndrom

210 reactive IgGs contribute to the pathology of autoimmune diseases, including systemic lupus erythemato

211 implied the association of IRF5 with several autoimmune diseases, including systemic lupus erythemato

212 arget autoantigens in several organ-specific autoimmune diseases, including type 1 diabetes (T1D), ar

213 egy to re-establish Ag-specific tolerance in autoimmune diseases, including type 1 diabetes (T1D).

214 Susceptibility and protection against human autoimmune diseases, including type I diabetes, multiple

215 rtunity for a wide range of inflammatory and autoimmune diseases, including uveitis.

216 Interestingly, Ltab-Ncr3 did not regulate autoimmune diseases induced with tissue-specific antigen

217 seases, including inflammatory rheumatic and autoimmune diseases, infections, and malignancies can mi

218 nt found in some patients afflicted with the autoimmune disease IPEX has broadened DNA-recognition sp

219 The occurrence of autoimmune disease is a negative prognostic factor for s

220 Of interest to the etiology of demyelinating autoimmune disease is the potential to aberrantly activa

221 A notable feature of many autoimmune diseases is their greater prevalence in femal

222 D) is primarily perceived as a T cell-driven autoimmune disease, islet autoantibodies are the best cu

223 Type 1 diabetes (T1D) is an autoimmune disease leading to beta-cell destruction.

224 its antiviral activity and association with autoimmune disease, leading to aberrant activation of in

225 IL-27 exerts protective effects in autoimmune diseases like experimental autoimmune encepha

226 tical for the development and maintenance of autoimmune diseases like rheumatoid arthritis (RA).

227 Primary membranous nephropathy (MN) is an autoimmune disease mainly caused by autoantibodies again

228 n to be involved in many disorders including autoimmune diseases, malignancies and pregnancy outcomes

229 Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies that targe

230 represent a potential avenue for combatting autoimmune diseases mediated by T reg cell dysfunction.

231 PLA2R is the target of the autoimmune disease, membranous nephropathy, characterise

232 In the autoimmune disease multiple sclerosis and its animal mod

233 Giant cell arteritis, a chronic autoimmune disease of the aorta and its large branches,

234 Multiple sclerosis (MS) is an autoimmune disease of the central nervous system.

235 Vitiligo is an autoimmune disease of the skin characterized by patchy d

236 Vitiligo is an autoimmune disease of the skin that results in the destr

237 epilepsy and in an array of degenerative and autoimmune diseases of the central nervous system.

238 CD177 presents antigens in allo- and autoimmune diseases on the neutrophil surface.

239 ars to understand people's susceptibility to autoimmune diseases or cancer, a role for environmental

240 sulin-reactive CD4(+) T cell development and autoimmune disease outcome.

241 inflammation in inflammatory conditions and autoimmune diseases, particularly inflammatory arthritis

242 st extracellular pathogens but also underlie autoimmune disease pathogenesis.

243 responses to DNA vaccines, gene therapy, and autoimmune disease pathogenesis.

244 ical B12 absorption, best exemplified by the autoimmune disease pernicious anemia.

245 tory agent in several models of inflammatory/autoimmune disease, promoting primarily Th17 development

246 Nanoparticles coated with autoimmune disease-relevant peptide-major histocompatibi

247 Current therapies for autoimmune diseases rely on traditional immunosuppressiv

248 ing their key effector functions in specific autoimmune diseases remains challenging.

249 emotherapy to grade 1 or less, had no active autoimmune disease requiring systemic steroids or immuno

250 f they had active brain metastases or active autoimmune disease requiring systemic steroids.

251 and maintenance of the chronic inflammatory autoimmune disease rheumatoid arthritis (RA); however, c

252 s: all genes, the set of genes implicated in autoimmune disease risk by GWAS, and the subset of these

253 t of previous methods to identify loci where autoimmune-disease risk and an eQTL are driven by a sing

254 Most autoimmune-disease-risk effects identified by genome-wid

255 Ideally, therapy for autoimmune diseases should eliminate pathogenic autoimmu

256 have been linked to chronic inflammatory and autoimmune diseases such as atherosclerosis, inflammator

257 ers with variants previously associated with autoimmune diseases such as Crohn disease, multiple scle

258 Hypoxia is essential for the development of autoimmune diseases such as rheumatoid arthritis (RA) an

259 istently, mutations in TREX1 are linked with autoimmune diseases such as systemic lupus erythematosus

260 ver, neutrophil activation is also linked to autoimmune diseases such as systemic lupus erythematosus

261 errant TFH cell expansion is associated with autoimmune diseases, such as systemic lupus erythematosu

262 ponse is a central driver of pathogenesis in autoimmune diseases, such as systemic lupus erythematosu

263 ommonalities in pathways between allergy and autoimmune diseases, suggesting shared disease mechanism

264 Multiple sclerosis (MS) is an autoimmune disease targeting the central nervous system

265 autoantibodies in myasthenia gravis (MG), an autoimmune disease that causes neuromuscular transmissio

266 Rheumatoid arthritis is a chronic autoimmune disease that causes progressive articular dam

267 Type 1 diabetes (T1D) is a chronic autoimmune disease that causes severe loss of pancreatic

268 Type 1 diabetes is a T cell-mediated autoimmune disease that is characterized by Ag-specific

269 We applied our method to RRMS, an autoimmune disease that is notoriously difficult to diag

270 Type 1 diabetes (T1D) is an autoimmune disease that results from the destruction of

271 Type 1 diabetes mellitus is a chronic autoimmune disease that results from the destruction of

272 Multiple sclerosis (MS) is a common autoimmune disease that targets myelin in the central ne

273 therapeutic application of NRF2 inducers in autoimmune diseases that are accompanied by Treg dysfunc

274 el studies and tests of hypotheses linked to autoimmune diseases that can co-segregate with schizophr

275 in the pathogenesis of several diseases, the autoimmune diseases that represent a relevant burden for

276 se activation of TLRs has been implicated in autoimmune diseases, the goal of this study was to deter

277 ex, previous venous thromboembolism, cancer, autoimmune disease, thrombosis of non-varicose veins).

278 l superantigens may precipitate a lupus-like autoimmune disease through activation of DNT cells.

279 rface, but also mediate pathology in certain autoimmune diseases through innate IL-17 production.

280 ontribute to the etiology of T-cell-mediated autoimmune diseases through the upregulation of type 2 a

281 enetic loci and pathways between allergy and autoimmune diseases to elucidate shared disease mechanis

282 ment of an array of diseases from cancer and autoimmune diseases to infectious diseases.

283 crucial to identify the occurrence of other autoimmune diseases, to control relapses, and to evaluat

284 portant pathological states such as cancers, autoimmune diseases, transplantation, and infection.

285 Adults with autoimmune disease treated with immunosuppressive therap

286 The rampant autoimmune disease was associated with enhanced T cell p

287 Among 290 loci previously associated with 16 autoimmune diseases, we found a significant enrichment o

288 Hi-C data with genetic associations for five autoimmune diseases, we prioritised 245 candidate genes

289 r the dominantly protective effect of HLA in autoimmune disease, whereby HLA polymorphism shapes the

290 IL-35 suppresses autoimmune diseases while preventing host defense to inf

291 f-peptide MHC complexes (self pMHC) to avoid autoimmune diseases, while positive selection ensures th

292 at use of EBI3 as a therapeutic biologic for autoimmune diseases will likely require co-administratio

293 lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a strong genetic component chara

294 Systemic lupus erythematosus (SLE) is an autoimmune disease with marked gender and ethnic dispari

295 Systemic sclerosis is an orphan, systemic autoimmune disease with no FDA-approved treatments.

296 ultimodular therapy when targeting cancer or autoimmune diseases with mAbs as well as the frequency a

297 is is now the most effectively treated human autoimmune disease, with high-level clinical improvement

298 in the fatigue and anorexia associated with autoimmune diseases, with major depression, and with une

299 pproach for T lymphocyte immunomodulation in autoimmune diseases without affecting other immune cells

300 In adults with autoimmune disease, ZVIN was well tolerated and elicited